Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia

• Autor(a) principal: Oliveira, Guilherme Augusto Piedade de
• Data de Publicação: 2010
• Outros Autores: Costa, Elaine Sobral da, Freitas, Mônica Santos de, Dutra, Fabiano Ferreira, Maia, S. F., Guerra, M. C., Tabernero, M. D., Borojevic, Radovan, Otazú, Ivone Beatriz, Silva, Jerson Lima da
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional do INMETRO
• Texto Completo: http://hdl.handle.net/10926/1547

Chronic myeloid leukemia (CML) is rare in the pediatric population, accounting for 2-3% of childhood leukemia cases, with an annual incidence of one case per million children. The low toxicity profile of imatinib mesylate has led to its approval as a front-line therapy in children for whom interferon treatment has failed or who have relapsed after allogeneic transplantation. We describe the positive responses of 2 children (case 1 - from a 7-year-old male since May 2005; case 2 - from a 5-year-old female since June 2006) with Philadelphia-positive chromosome CML treated with imatinib (300 mg/day, orally) for up to 28 months, as evaluated by morphological, cytogenetic, and molecular approaches. Our patients are alive, are in the chronic phase, and are in continuous morphological complete remission.